“US Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline Insight 2025” Report Highlights:
- US Breast Cancer Drug Market Opportunity: US$ 20 Billion
- US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class & Patient Segment
- US Breast Cancer Marketed Drugs: 42 Drugs
- US Breast Cancer Drug Clinical Pipeline: 317 Drugs
- Dosage & Pricing Insight for Preventive & Treatment Drugs
- US Breast Cancer Drug Market Dynamics
Download Report: https://www.kuickresearch.com/report-us-breast-cancer-drug-market,-price,-dosage-and-clinical-pipeline-insight-2025.php
Table of Contents
1. US – Cancer Incidence and Prevalence
2. US Breast Cancer Market Landscape
2.1 Incidence and Prevalence
2.2 Diagnosis of Breast Cancer
3. US Breast Cancer Drug Market
3.1 Overview US Breast Cancer Drug Market
3.2 Diagnosis and Screening Market Scenario
3.3 US Breast Cancer Clinical Pipeline Overview (Phase, Drug Class, Company, Patient Segment)
4. Forward Looking Developments in Breast Cancer Drug Market
4.1 ER Positive Breast Cancer
4.1.1 CDK4/6 Inhibitors
4.1.2 PI3K Inhibitors
4.1.3 Crizotinib for Lobular Breast Cancer
4.2 HER2-Positive Breast Cancer
4.2.1 Palbociclib and Herceptin (Spain)
4.2.2 Tecentriq – FDA Approval for Breast Cancer
4.3 Triple Negative Breast Cancer
4.3.1 Atezolizumab and Nab-Paclitaxel
4.3.2 Sacituzumab Govitecan
4.3.3 Carboplatin and Docetaxel
5. US – Dosage and Pricing Insight for Drugs Approved for the Prevention of Breast Cancer
5.1 Raloxifene Hydrochloride
5.2 Elvista
5.3 Tamoxifen Citrate
6. US – Dosage and Pricing Insight for Drugs Approved for the Treatment of Breast Cancer
6.1 Abemaciclib
6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
6.3 Ado-Trastuzumab Emtansine
6.4 Afinitor (Everolimus)
6.5 Anastrozole
6.6 Aromasin (Exemestane)
6.7 Xeloda (Capecitabine)
6.8 Docetaxel (Docetaxel Anhydrous)
6.9 Doxorubicin Hydrochloride
6.10 Ellence (Epirubicin Hydrochloride)
6.11 Fluorouracil
6.12 Taxol (Paclitaxel)
6.13 Methotrexate
6.14 Cyclophosphamide
7. US Breast Cancer Drug Market Dynamics
7.1 Market Drivers
7.1.1 Increasing Incidence of Breast Cancer
7.1.2 Research and Development for Novel Drugs
7.1.3 Increase in Healthcare Expenditure and Funding
7.1.4 Increasing Breast Cancer Screening Programs
7.1.5 Rising Consumption of Tobacco and Alcohol
7.2 US Breast Cancer Drug Market Challenges
7.2.1 Pricing Pressure Experienced by the Innovators
7.2.2 High Cost associated with Drug Development and Clinical Trials
7.2.3 Obstacles to the Incorporation of New Therapies for Breast Cancer
8. US – Breast Cancer Drug Market Forecast
8.1 Future Potential of US Breast Cancer Drug Market
8.2 Opportunities for Forthcoming Drug Classes
9. US – Breast Cancer Drug Clinical Pipeline by Company and Phase
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-II/III
9.8 Phase-III
9.9 Preregistration
9.10 Registered
10. US – Marketed Breast Cancer Drug Clinical Insight by Company
10.1 Afinitor
10.2 LYNPARZA
10.3 Abraxane
10.4 Verzenio
10.5 Kisqali
10.6 Lymphoseek
10.7 Kadcyla
10.8 Ibrance
10.9 Nerlynx
10.10 Soltamox
10.11 Tykerb
10.12 Zoladex
10.13 Omnitarg, Perjeta
10.14 Halaven
10.15 Taxotere
10.16 Other( 27 Drugs Profiles)
11. Competitive Landscape
11.1 Agilent Technologies
11.2 AstraZeneca
11.3 Bayer HealthCare Pharmaceuticals
11.4 Bristol-Myers Squibb
11.5 Eisai Co Ltd
11.6 Eli Lilly
11.7 Novartis
11.8 Onyx Pharmaceuticals
11.9 Orion
11.10 Perrigo
11.11 Pfizer
11.12 Roche
Contact For Sample:
Neeraj Chawla
neeraj@kuickresearch.com
+91-11-47067990